Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2486-2492

  Huang, Yu ^a   Chen, Yu ^a   Mei, Qin ^a   Chen, Yuan ^a   Yu, Shiying ^a   Xia, Shu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

EGFR; mTOR; Non small cell lung cancer; PIK3CA

Indexed keywords

EVEROLIMUS; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EGFR SIGNALING PATHWAY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MTOR SIGNALING PATHWAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84876269718     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2357     Document Type: Article

References (30)

1. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
2. Wheeler DL, Dunn EF and Harari PM: Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat Rev Clin Oncol 7: 493-507, 2010.
3. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.
4. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002. (Pubitemid 34074005)
5. Engelman JA, Janne PA and Mermel C: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788-3793, 2005. (Pubitemid 40354690)
6. Gorzalczany Y, Gilad Y, Amihai D, Hammel I, Sagi-Eisenberg R and Merimsky O: Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. Cancer Lett 310: 207-215, 2011.
7. Morrow PK, Wulf GM, Ensor J, et al: Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29: 3126-3132, 2011.
8. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F and Tortora G: Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98: 923-930, 2008. (Pubitemid 351341618)
9. Zoncu R, Efeyan A and Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2010.
10. Yea SS and Fruman DA: Cell signaling. New mTOR targets Grb attention. Science 332: 1270-1271, 2011.
11. Atkins MB, Yasothan U and Kirkpatrick P: Everolimus. Nat Rev Drug Discov 8: 535-536, 2009.
12. Mordant P, Loriot Y, Leteur C, et al: Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther 9: 358-368, 2010.
13. Goldoni M and Johansson C: A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro 21: 759-769, 2007. (Pubitemid 46603249)
14. Noro R, Gemma A, Kosaihira S, et al: Gefitinib (Iressa) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 6: 277, 2006.
15. Di Nicolantonio F, Arena S, Tabernero J, et al: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866, 2010.
16. Balko JM, Jones BR, Coakley VL and Black EP: Combined MEK and EGFR inhibition demonstrates synergistic activity in EGFR-dependent NSCLC. Cancer Biol Ther 8: 522-530, 2009.
17. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003. (Pubitemid 36687658)
18. Dobashi Y, Suzuki S, Kimura M, et al: Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Human Pathol 42: 214-226, 2011.
19. Yu Y, Yoon SO, Poulogiannis G, et al: Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332: 1322-1326, 2011.
20. Hsu PP, Kang SA, Rameseder J, et al: The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332: 1317-1322, 2011.
21. Shi Y, Yan H, Frost P, Gera J and Lichtenstein A: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4: 1533-1540, 2005. (Pubitemid 41556435)
22. Goudar RK, Shi Q, Hjelmeland MD, et al: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4: 101-112, 2005. (Pubitemid 40268071)
23. Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM and Drabkin HA: Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer 92: 2266-2277, 2005. (Pubitemid 40966266)
24. Price KA, Azzoli CG, Krug LM, et al: Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 5: 1623-1629, 2010.
25. La Monica S, Galetti M, Alfieri RR, et al: Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78: 460-468, 2009.
26. Vienna L, Fortunato B, Lorenza P, et al: Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 6: 707-715, 2011.
27. Elizabeth B, Alexandra E, Eric B, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2627-2684, 2006.
28. Magali R, Paul P, Amelie D, et al: Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in by passing this resistance. Int J Oncol 38: 189-200, 2011.
29. Tamburini J, Green AS and Bardet V: Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114: 1618-1627, 2009.
30. Mohseni M and Park BH: PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. J Clin Invest 120: 2655-2658, 2010.